GlassScriptPhysician profile
Tassia M Samona
NPI 1891175048
$4,603.39
in general payments reported to CMS, 2019-2025
35 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $96.10 · 2021: $381 · 2022: $571 · 2023: $583 · 2024: $933 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $615.89 | 2019-2025 | |
| Novo Nordisk INC | $576.08 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $511.24 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $467.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $390.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $360.36 | 2019-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $260.29 | 2022-2024 | |
| Astellas Pharma US INC | $200.36 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $117.88 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $112.73 | 2021-2025 | |
| Glaxosmithkline, LLC. | $112.39 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $92.05 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $81.26 | 2019-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.83 | 2019-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $67.50 | 2022-2023 | Quviviq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $65.51 | 2022-2025 | Givlaari |
| Axsome Therapeutics, INC. | $64.74 | 2025 | Auvelity |
| Genentech USA, INC. | $43.14 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $40.44 | 2019 | |
| Dexcom, INC. | $40.18 | 2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $35.37 | 2022-2023 | Aplenzin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.59 | 2022-2025 | Jardiance |
| Circassia INC. | $29.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.73 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.72 | 2019 | |
| Dynavax Technologies Corporation | $19.31 | 2023 | Heplisav-B |
| Seqirus USA INC | $18.93 | 2022 | |
| Corium, LLC | $18.31 | 2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $17.94 | 2022 | |
| Ibsa Pharma INC. | $17.46 | 2022 | |
| Eisai INC. | $16.43 | 2019 | |
| Endo Pharmaceuticals INC. | $14.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.08 | 2024 | Eliquis |
| Vivaquant INC, Dba Rhythm Express | $12.92 | 2024 | Rhythm Express |
| Therapeuticsmd, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tassia Samona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.